Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hemoglobinuria, Paroxysmal 4Neoplasms 2Melanoma 2Leukemia 2Hodgkin Disease 2Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Neuroblastoma 1Lymphoma 1Liver Neoplasms 1Histiocytosis 1Hemoglobinuria 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

atezolizumab 1Paclitaxel 1Carboplatin 1Antibodies 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Squamous Non-Small Cell Lung Cancer × Antibodies × Clear all
NCT02367794 2022-03-21

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Hoffmann-La Roche

Phase 3 Completed
1,021 enrolled 33 charts
Thoracic

Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡